NEUE (NeueHealth) EBIT: $-35.7 Mil (TTM As of Jun. 2025)

What is NeueHealth EBIT?

NeueHealth NEUE 20 EBIT is $-35.7 Mil as of Jun. 2025. GuruFocus rates NEUE with a GF Score™ of 20/100 and a GF Value™ of $8.81. The stock has 6 warning signs investors should review.

NeueHealth's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2025 was $13.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was $-35.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NeueHealth's annualized ROC % for the quarter that ended in Jun. 2025 was 6.66%. NeueHealth's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 481.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NeueHealth's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -3.23%.

NeueHealth (NYSE:NEUE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NeueHealth's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

	ROC % (Q: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2025 )	+	Invested Capital (Q: Jun. 2025 ))	/ count )
=	57.028 * ( 1 - 0% )	/	( (928.244	+	785.084)	/ 2 )
=	57.028	/	856.664
=	6.66 %

where

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	895.68	-	243.282	-	( 145.105	-	max(0, 1064.052	-	788.206	+	145.105	))
=	928.244

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	743.689	-	227.135	-	( 145.564	-	max(0, 908.412	-	639.882	+	145.564	))
=	785.084

Note: The Operating Income data used here is four times the quarterly (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

NeueHealth's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2025		Q: Jun. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	54.78	/	( ( (11.108 + max(-419.951, 0))	+	(11.664 + max(-413.094, 0)) )	/	2 )
=	54.78	/	( ( 11.108	+	11.664 )	/	2 )
=	54.78	/	11.386
=	481.12 %

where Working Capital is:

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(510.062	+	0	+	133.039)	-	(243.282	+	0	+	819.77)
=	-419.951

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(374.67	+	0	+	119.648)	-	(227.135	+	0	+	680.277)
=	-413.094

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NeueHealth's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2025 )
	=	-35.7	/	1104.956
	=	-3.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeueHealth EBIT Related Terms

NeueHealth EBIT Historical Data

* Premium members only.

The historical data trend for NeueHealth's EBIT can be seen below:

NeueHealth EBIT Chart

NeueHealth Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-170.38

-342.40

-368.76

-590.97

-80.76

NeueHealth Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25
EBIT	Get a 7-Day Free Trial															-35.34	-17.80	-36.90	5.31	13.70

NEUE vs PFHO, UNH, CVS: EBIT Comparison

For the Healthcare Plans subindustry, NeueHealth's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeueHealth EV-to-EBIT vs Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, NeueHealth's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NeueHealth's EV-to-EBIT falls into.

Save Embed

20GF Score

NeueHealth Inc NEUE

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NeueHealth EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.7 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-35.7 Mil mean?

NeueHealth (NEUE) has a EBIT of $-35.7 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NeueHealth.

Is NeueHealth's EBIT too high?

NeueHealth's current EBIT is $-35.7 Mil. Overall, NeueHealth has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.

How does NeueHealth's EBIT compare to PFHO and UNH?

NeueHealth's EBIT of $-35.7 Mil can be compared against companies in the Healthcare Plans industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Healthcare Plans company?

A good EBIT depends on the Healthcare Plans industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NeueHealth. NeueHealth's current EBIT is $-35.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NeueHealth stock overvalued right now?

NeueHealth (NEUE) has a current EBIT of $-35.7 Mil. The stock's GF Value™ is $8.81, compared to a current price of $6.75 — trading 23.3% below its estimated fair value. The current EBIT is $-35.7 Mil. NeueHealth's overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For NeueHealth (NEUE), the current EBIT is $-35.7 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeueHealth (NEUE) Overvalued in 2026?

Based on GuruFocus' analysis, NeueHealth stock appears to be undervalued. The current stock price of $6.75 is trading 23.3% below its estimated GF Value™ of $8.81.

Key valuation signals for NEUE:

EBIT: $-35.7 Mil
GF Value™: $8.81 vs. price of $6.75 (23.3% below fair value)
GF Score™: 20/100 with 6 warning signs

No single metric tells the full story. See the NEUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeueHealth Business Description

Industry Healthcare Healthcare Plans

Comparable Companies PFHO UNH CVS CI ELV HUM CNC MOH OSCR ALHC PGNY CLOV SZSE:000503 BSP:ODPV3 NSE:MEDIASSIST BJSE:870656 BSP:QUAL3 MIL:HI ROCO:6665

Address 9250 NW 36th Street, Suite 420, Doral, FL, USA, 33178

Website https://www.neuehealth.com

NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.

20GF Score

Get the complete analysis for NEUE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.75

Price

$8.81

GF Value

View NEUE Analysis

See EBIT data for all stocks →